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Abstract
Background: The 26S proteasome is responsible for most
cytosolic proteolysis, and is an important protease in major
histocompatibility complex class I-mediated antigen presentation.
Constitutively expressed proteasomes from mammalian sources
possess three distinct catalytically active species, L1, L2 and L5,
which are replaced in the Q-interferon-inducible immunoprotea-
some by a different set of catalytic subunits, L1i, L2i and L5i,
respectively. Based on preferred cleavage of short fluorogenic
peptide substrates, activities of the proteasome have been assigned
to individual subunits and classified as ‘chymotryptic-like’ (L5),
‘tryptic-like’ (L2) and ‘peptidyl-glutamyl peptide hydrolyzing’ (L1).
Studies with protein substrates indicate a far more complicated,
less strict cleavage preference. We reasoned that inhibitors of
extended size would give insight into the extent of overlapping
substrate specificity of the individual activities and subunits.
Results : A new class of proteasome inhibitors, considerably
extended in comparison with the commonly used fluorescent
substrates and peptide-based inhibitors, has been prepared.
Application of the safety catch resin allowed the generation of
the target compounds using a solid phase protocol. Evaluation of
the new compounds revealed a set of highly potent proteasome
inhibitors that target all individual active subunits with compar-
able affinity, unlike the other inhibitors described to date.
Modification of the most active compound, adamantane-acetyl-
(6-aminohexanoyl)3-(leucinyl)3-vinyl-(methyl)-sulfone (Ada-
Ahx3L3VS), itself capable of proteasome inhibition in living cells,
afforded a new set of radio- and affinity labels.
Conclusions: N-terminal extension of peptide vinyl sulfones has
a profound influence on both their efficiency and selectivity as
proteasome inhibitors. Such extensions greatly enhance inhibition
and largely obliterate selectivity towards the individual catalytic
activities. We conclude that for the interaction with larger
substrates, there appears to be less discrimination of different
substrate sequences for the catalytic activities than is normally
assumed based on the use of small peptide-based substrates and
inhibitors. The compounds described here are readily accessible
synthetically, and are more potent inhibitors in living cells than
their shorter peptide vinyl sulfone counterparts. ß 2001 Elsevier
Science Ltd. All rights reserved.
Keywords: Active site label ; Inhibitor; Peptide vinyl sulfone;
Proteasome; Substrate analog
1. Introduction
The 26S proteasome, a large cytosolic protease complex,
is implicated in many biological processes [1^3], including
degradation of most cytosolic proteins in mammalian cells
and generation of antigenic peptides presented by major
histocompatibility complex class I (MHC I) molecules
[4,5]. The 26S proteasome is composed of an inner 20S
core, with which two 19S caps are associated. The 19S
caps contain elements responsible for recognition of ubiq-
uitinated protein substrates and unfolding of substrates
targeted to the proteasome in an ATP-dependent manner,
whereas the actual proteolytic activity resides in the inner
20S core. In addition to the 19S caps, other multisubunit
complexes, such as PA28, modulate proteasome activity.
The 20S particle itself consists of 28 individual subunits
arranged in cylindrical form of four rings containing seven
subunits each. The outer rings, which interact with the
19S regulatory caps, consist of seven highly homologous
K-subunits. The two inner rings are assembled from seven
distinct L-subunits each, three of which in each ring are
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catalytically active. In higher vertebrates, these proteolytic
L-subunits, L1, L2 and L5, respectively (also referred to as
the Y, Z and X subunits), are thought to display three
distinct catalytic activities, commonly referred to as the
chymotryptic-like activity (attributed to L5), peptidyl-glu-
tamyl peptide hydrolyzing activity (PGPH; L1) and tryp-
tic-like activity (L2). Upon exposure to Q-interferon
(IFNQ), antigen presenting cells (APCs) express an addi-
tional set of catalytic L-subunits. These subunits, L1i, L2i
and L5i (also referred to as LMP2, MECL-1 and LMP7),
replace L1, L2 and L5, respectively, to form a new particle,
the immunoproteasome [2]. The 19S caps may be replaced
by the 11S or PA28 regulatory complex, itself induced by
IFNQ.
The precise role of the individual activities in cytosolic
proteolysis remains unclear. In a broader sense, this also
holds true for our understanding of the immunological
necessity for expressing the immunoproteasome to gener-
ate antigenic peptides. Whereas an essential role of the
immunoproteasome in the generation of suitable oligopep-
tides for MHC I-mediated antigen presentation is now
widely accepted, our understanding of the di¡erent sub-
strate speci¢cities of the corresponding catalytic L-subunits
for the constitutive proteasome and the immunoprotea-
some is incomplete. In vitro studies [6,7], in which proteins
are exposed to puri¢ed 20S proteasomes, followed by
analysis of the produced oligopeptides, do not necessarily
re£ect cleavage patterns that occur in vivo under the in-
£uence of the 26S proteasome [8,9]. Current knowledge of
both the catalytic mechanism and the substrate speci¢city
of the various catalytic proteasomal L-subunits is based
largely on the use of synthetic proteasome inhibitors and
arti¢cial, £uorogenic substrates [10]. For several such in-
hibitors, the structure of the 20S proteasome complex with
inhibitor has been solved [11^13]. Indeed, the designation
‘chymotryptic-like, PGPH and tryptic-like’ hydrolyzing
activities, and their assignment to L5, L1 and L2, respec-
tively, is based on proteasomal hydrolysis of £uorogenic
substrates [14].
Proteasome inhibitors have proven essential to study
proteasome activity in living cells. Well-known protea-
some inhibitors include lactacystin [15], epoxomicin [16]
as well as the peptide vinyl sulfones NLVS [17] and
YL3VS [18] (Fig. 1). Most proteasome inhibitors, with
the fungal metabolite lactacystin as a notable exception,
are based on short oligopeptidic sequences, in which the
C-terminus (or P1 position) has been replaced with an
electrophilic trap, such as an aldehyde [19], a boronate
[20] (both of which result in reversible inhibitors), an ep-
oxyketone or a vinyl sulfone [17,18] (generating irrevers-
ible inhibitors). Important goals are the development of
inhibitors that are subunit-speci¢c and cell-permeable. At
the same time, inhibitors that inactivate all L-subunits ef-
¢ciently and that retain cell permeability would also be
useful for both in vitro and in vivo applications. To
date, however, none of the available inhibitors targets all
L-subunits equally well. Considerable progress in the de-
velopment of subunit-speci¢c inhibitors has been made by
Crews and coworkers, who, by variation of the sequence
at P2^P4 in epoxomicin, were able to generate speci¢c
inhibitors of the ‘chymotryptic-like’ [21] and ‘PGPH’ [22]
activities, respectively. Research from our laboratory has
shown peptide vinyl sulfones to be potent proteasome in-
hibitors [17,18]. Based on the trileucine vinyl sulfone core,
introduction of di¡erent substituents at P4 yielded inhib-
itors with a preference for L5 (NLVS) and L2 (YL3VS),
respectively, as corroborated by their radiolabeled ana-
logs. More recently, Nazif and Bogyo [23] reported the
preparation of a peptide vinyl sulfone library with aspar-
agine vinyl sulfone at P1 that yielded highly speci¢c inhib-
itors of L2.
The assignment of substrate speci¢city based on small
peptide-based inhibitors, as well as their corresponding
substrates, is rather complicated. This is perhaps best il-
lustrated by the fact that the only e¡ective, selective inhib-
itor of the ‘PGPH’ activity (sometimes referred to as the
‘caspase-like’ or ‘postacidic’ activity depending on the
£uorogenic substrate used [24]) in fact contains a leucine
epoxyketone moiety (rather than the corresponding gluta-
mate or aspartate derivative) at P1 [22]. We reasoned that
it would be desirable to have access to inhibitors which, at
least in size, are closer to the natural substrate of the
proteasome, that is, presumably, an extended polypeptide
chain. Obviously, retention of cell permeability is essential
if such inhibitors are to be used in living cells.
Here we report the design and synthesis of a set of novel
proteasome inhibitors. The compounds consist of the core
trileucine vinyl sulfone moiety and are extended with a
number of aminohexanoic acid (Ahx) spacers, followed
by N-terminal caps of di¡erent size. Ahx spacers were
chosen to retain at least some amide linkages, while re-
moving features that might make such extensions cleav-
able. Even though side chains are obviously absent from
these spacers, the spacers themselves as well as their fur-
ther modi¢cation allow the introduction of substantial ad-
Fig. 1. Proteasome inhibitors. With the exception of lactacystin, protea-
some inhibitors are based on small oligopeptide sequences, the C-termi-
nus of which is modi¢ed to an electrophilic trap, such as an epoxyke-
tone (epoxomicin) or vinyl sulfone (NLVS, YL3VS).
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ditional mass. A total solid phase synthesis strategy using
Kenner’s safety catch linker proved to be very suitable for
the generation of the target compounds. Characterization
of these new proteasome inhibitors showed that the inhib-
itory properties increased dramatically upon increasing the
size of the extensions on the inhibitors. Furthermore, se-
lectivity for individual subunits is largely obliterated upon
extension of the inhibitors. These results suggest a higher
degree of overlap in speci¢city between the di¡erent cata-
lytic L-subunits of the proteasome than is currently as-
sumed based on the use of small proteasome inhibitors
and substrates. The most potent inhibitor of the series
proved to be cell-permeable and could be derivatized
into a radio- and an a⁄nity label. We demonstrate appli-
cations of these compounds in the study of proteasomal
function in vitro and in living cells.
2. Results
2.1. Design and synthesis of N-terminally extended
proteasome inhibitors
Peptide vinyl sulfones covalently and irreversibly modify
the catalytically active L-subunits of the proteasome
through a Michael reaction with the hydroxyl moiety of
the N-terminal threonine residue. Depending on N-termi-
nal modi¢cation, peptides containing the core trileucine
vinyl sulfone structure (L3VS) can target both L2 and
L5. Introduction of di¡erent substituents at the N-termi-
nus (P4) led to inhibitors with selectivity leaning towards
L5/L5i (NLVS, ZL3VS) or L2/L2i (YL3VS). We therefore
decided to use the L3VS core as a basis for the generation
of new proteasome inhibitors with N-terminal extensions
of varied size and composition (Fig. 2).
An obvious approach for the construction of N-termi-
nally extended peptide vinyl sulfones would be elongation
with natural amino acids. However, we found that com-
pounds of this type are less desirable as proteasome inhib-
itors due to their susceptibility to proteasomal cleavage
internally (B.M. Kessler and H.L. Ploegh, unpublished
results). This observation led us to select 6-Ahx as a suit-
able linker molecule between the trileucine vinyl sulfone
core and di¡erent N-terminal caps, such as acetate (Ac),
benzyloxycarbonylate (Z) and adamantanylacetate (Ada)
substituents. The adamantane moiety was chosen because
earlier work with substituted azasugars showed promise
for this modi¢cation to retain cell permeability [25]. Ada-
mantanylacetic acid was incorporated either as a single
residue (as in 5^8, 11, 12, 17) or as a dimer linked through
diaminopropionic acid (Dpr, 15, 16). Incorporation of ty-
rosine (Y, 9^12, 14, 16) or O-biotinyl-lysine (K(Bio), 17)
near the N-terminus allowed radiolabeling or streptavidin-
mediated detection, respectively, of the modi¢ed proteaso-
mal L-subunits.
The target compounds were prepared by either one of
Fig. 2. Design of a new class of substrate-like proteasome inhibitors.
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two independent synthetic routes (Scheme 1). We recently
reported [26] the solid phase synthesis of peptide vinyl
sulfone and peptide epoxyketone-based proteasome inhib-
itors, including ZL3VS 1. Our strategy is based on the
protocols described by Ellman and coworkers [27] who
utilized a modi¢cation of Kenner’s safety catch linker
[28] for the synthesis of libraries of £uorogenic peptide
substrates [29].
The complete panel of compounds 1^17 has been pre-
pared starting from the safety catch resin, as is illustrated
for AdaYAhx3L3VS 11 (route A, Scheme 1). 4-Sulfamyl-
butyrylaminomethyl polystyrene resin (the ‘safety catch’
resin) was functionalized with Fmoc-leucine following
the published procedure [26]. Standard Fmoc-based solid
phase peptide synthesis (SPPS) a¡orded the immobilized
protected oligopeptide. Activation of the resin was then
accomplished using a 50-fold excess of iodoacetonitrile
in the presence of N,NP-diisopropylethylamine (DiPEA,
10 equivalents) in N-methylpyrrolidinone (NMP). Treat-
ment of the activated resin with leucine vinyl sulfone (10
equivalents) and DiPEA (12 equivalents) in dimethyl
formamide (DMF, 4 days), and subsequent removal of
the tert-butyl protective group (tri£uoroacetic acid
(TFA)/H2O/triisopropylsilane (TIS) 95/2.5/2.5), yielded
the target peptide vinyl sulfone, which was puri¢ed using
reverse phase high performance liquid chromatography
(HPLC). Following the safety catch route, the target pep-
tides could be routinely prepared on a 50 Wmol scale with
puri¢ed yields varying from 5 to 30%.
Peptide vinyl sulfones 4, 7, 11 and 17 were prepared on
a larger scale (0.5^1.0 mmol) following a block coupling
protocol [21], as outlined for AdaYAhx3L3VS 11 (route B,
Scheme 1). Starting from the Wang resin, SPPS followed
by acid-mediated cleavage a¡orded AdaYAhx3L2OH.
Treatment with leucine vinyl sulfone under the agency of
O-benzotriazol-1-yl-N,N,NP,NP-tetramethyluronium hexa-
£uorophosphate (HBTU) and DiPEA in DMF, followed
by concentration in vacuo and precipitation from ethyl
acetate a¡orded the target compound 11 in 90% analytical
purity. Yields for compounds 4, 7, 11 and 17 typically
varied from 45 to 50%. Although in theory compounds
1^17 are all accessible following the block coupling route,
the generation of peptide vinyl sulfones featuring acidic or
basic side chain residues through block coupling would
obviously require a more elaborate protective group strat-
egy. We ¢nd that peptide vinyl sulfones containing such
residues as glutamate, lysine or arginine are more conven-
iently prepared using the safety catch resin (H.S. Over-
kleeft and H.L. Ploegh, unpublished results).
2.2. N-terminal extension dramatically increases
proteasome inhibition
As an initial experiment, we assayed the inhibition po-
tency of proteasome inhibitors 1^8 (Fig. 3B). Competition
experiments were carried out in which we examined the
ability of the new proteasome inhibitors to inhibit labeling
of proteasomal subunits with 125I-YL3VS (targeting
L2/L2i) or 125I-NLVS (targeting L5/L5i). Cell lysates from
EL-4 cells, a mouse cell line that expresses both the
constitutive proteasome and the immunoproteasome,
were incubated with ZL3VS 1, ZAhxL3VS 2, ZAhx3L3VS
3, ZAhx5L3VS 4, AdaL3VS 5, AdaAhxL3VS 6,
AdaAhx3L3VS 7 and AdaAhx5L3VS 8, respectively, at
concentrations ranging from 0 to 30 WM. As further con-
trols, we included NLVS, YL3VS and epoxomicin. Resid-
Scheme 1. Synthesis of the proteasome inhibitors. The designed proteasome inhibitors can be prepared using two di¡erent synthetic routes. Compounds
1^17 were prepared using the safety catch resin, as illustrated for AdaYAhx3L3VS 11 (route A). Alternatively, a conventional block coupling was ap-
plied to synthesize compounds 4, 7, 11 and 17, also illustrated for AdaYAhx3L3VS 11 (route B).
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ual available subunits were labeled by a subsequent incu-
bation with either 125I-YL3VS or 125I-NLVS. Labeled sub-
units were then resolved by sodium dodecylsulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE) and
autoradiography. The intensity of labeled bands corre-
sponding to relevant subunits (125I-YL3VS-labeled L2,
the 125I-NLVS-labeled L5/L5i/L1 polypeptides as well as
the 125I-NLVS-labeled L1i) was quanti¢ed by densitome-
try. IC50 values (the concentration of inhibitor at which
labeling intensity is reduced by 50%) for each compound
were calculated (Fig. 3B).
An increase in the number of Ahx residues from zero
Fig. 3. N-terminal extension in£uences proteasome inhibition. A: Compounds 5^8 were added to EL-4 lysates prior to labeling with 125I-YL3VS. La-
beled polypeptides were separated by SDS^PAGE and analyzed by autoradiography; the L1, L5 and L5i polypeptides comigrate in this separation. Inhi-
bition is evident from the disappearance of the labeled proteasomal subunits when test compounds are included. B: IC50 values for the concentrations
at which compounds 1^8, NLVS, YL3VS and epoxomicin inhibit 50% of labeling of proteasomal subunits by 125I-YL3VS (L2) and 125I-NLVS (L1, L1i,
L5, L5i) were determined by densitometry analysis and normalized to 100%.
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Fig. 4. Elements distal from the pharmacophore in£uence inhibition pro¢les. A: Compounds 9, 11, 14 and 16 were added to EL-4 lysates prior to label-
ing with 125I-YL3VS. B: IC50 values for the concentrations in which compounds 3, 7, 9, 11, 11-I, 13, 14, 15, 16 and 17 inhibit 50% of labeling of pro-
teasomal subunits by 125I-YL3VS (L2, L2i) and 125I-NLVS (L1, L1i, L5, L5i) were determined by densitometry analysis and normalized to 100% (** indi-
cates no inhibition at 30 WM).
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(ZL3VS 1), to one (ZAhxL3VS 2), three (ZAhx3L3VS 3)
and ¢ve (ZAhx5L3VS 4) dramatically increases inhibition
potency, regardless of whether 125I-YL3VS or 125I-NLVS
is used as the label. A loss of subunit speci¢city thus cor-
relates with increased inhibition. Especially striking is the
e¡ect on L2 exerted by ZAhx5L3VS 4 : at a concentration
as low as 0.3 WM, subsequent labeling of this subunit with
125I-YL3VS is all but abolished, whereas the parent com-
pound ZL3VS 1 hardly targets L2 even at a 100-fold high-
er concentration. We note that the introduction of multi-
ple Ahx spacers does not confer onto these compounds
detergent-like properties. In vitro, the 20S proteasome is
activated by low concentrations of SDS (0.01%). As a
sensitive measure of any detergent-like properties, we com-
pared the e¡ect of 0.01% SDS with that of AdaAhx3L3VS
on the integrity of EL-4 cells. Whereas 0.01% SDS readily
lysed EL-4 cells, as measured by trypan blue exclusion,
AdaAhx3L3VS 7 at 0.01% w/v (107 WM) did not result
in any detectable cell lysis (data not shown). As we shall
show below, cells that express a reporter substrate which
accumulates in the cytosol upon inactivation of the pro-
teasome likewise retain this cytosolic reporter protein in
the presence of AdaAhx3L3VS 7.
A similar trend is observed in the experiments with com-
pounds AdaAhx3L3VS 5^AdaAhx5L3VS 8, containing the
more bulky hydrophobic Ada group as the N-terminal
cap. However, optimal inhibition is now observed for
AdaAhx3L3VS 7 (Fig. 3A), with three Ahx residues rather
than ¢ve, as in ZAhx5L3VS 4. At 0.3 WM of
AdaAhx3L3VS 7, labeling with 125I-YL3VS is largely abol-
ished, AdaAhx5L3VS 8 being a weaker inhibitor (Fig. 3).
Comparison with known proteasome inhibitors shows that
both ZAhx5L3VS 4 and AdaAhx3L3VS 7 are considerably
more potent inhibitors of the proteasome than YL3VS and
NLVS, and are comparable to the natural product epox-
omicin.
2.3. Elements distal from the pharmacophore in£uence
inhibition pro¢les
The results described above demonstrate the in£uence of
elements quite distal from P1 on proteasomal inhibition.
Although both ZAhx3L3VS 3 and AdaAhx3L3VS 7 are
potent inhibitors, introduction of the Ada moiety at the
N-terminus clearly has a bene¢cial e¡ect when compared
with the Z group. We therefore examined the e¡ect of the
size of the N-terminal cap in more detail (Fig. 4). EL-4
lysates were treated with AcAhx3L3VS 13 and
AdaDpr(Ada)Ahx3L3VS 15 prior to labeling with either
125I-NLVS or 125I-YL3VS, in an experiment similar to
that described above. Inhibition of labeling was compared
with ZAhx3L3VS 3 and AdaAhx3L3VS 7, and showed a
maximal inhibition for AdaAhx3L3VS 7 (Fig. 4B).
To transform the most e¡ective inhibitors into active
site probes, a tyrosine residue was incorporated to allow
labeling with 125I, and yielded AcYAhx3L3VS 14,
ZYAhx3L3VS 9, AdaYAhx3L3VS 11 and
AdaDpr(Ada)YAhx3L3VS 16. We ¢rst examined unla-
beled 9, 11, 14 and 16 in a competition experiment (Fig.
4A,B). As before, optimal inhibition is achieved when a
single Ada (as in 11) is present at the N-terminus. Com-
parison between ZYAhx5L3VS 10 and AdaYAhx5L3VS 12
revealed favorable inhibition properties for the former
compound, in line with those observed for compounds 4
and 8 (data not shown). Acetylated compounds 13 and 14
are poor inhibitors (IC50 values have dropped below those
observed for the small peptide vinyl sulfones ZL3VS,
NLVS and YL3VS), further underlining the important
contributions of distal elements of these inhibitors to pro-
teasomal inhibition. Although not the most potent inhib-
itors in this series, compounds 15 and 16, with two bulky
Ada groups at the N-terminus, still inactivate the protea-
some as e⁄ciently as the standard peptide vinyl sulfones.
2.4. Generation of novel proteasomal active site labels
A major advantage of covalent, irreversible proteasome
inhibitors, compared to their reversible counterparts, is
their ability, through radio- or a⁄nity labeling, to visual-
ize the subunits targeted. Whereas competition experi-
ments using £uorogenic substrates provide at best indirect
information on the selectivity of newly designed inhibitors
for individual proteasomal subunits, radiolabeled protea-
some inhibitors address subunit speci¢city unambiguously,
as demonstrated for [3H]lactacystin [30], and in our labo-
ratory for 125I-NLVS and 125I-YL3VS [14,15]. Likewise,
incorporation of a biotin moiety into the inhibitor allows
streptavidin-mediated visualization of the targeted sub-
units, as exempli¢ed by the biotinylated epoxomicin deriv-
atives reported by Crews and coworkers [31,32].
Incorporation of a tyrosine in close proximity to the
N-terminus of the newly designed proteasome inhibitors
does not signi¢cantly alter inhibitory potency (Fig. 4B,
AdaAhx3L3VS 7 vs AdaYAhx3L3VS 11). Alternatively,
introduction of a phenolic moiety at the C-terminal por-
tion of the inhibitors can be accomplished using leucine
vinyl (hydroxyphenyl) sulfone (LeuVS-PhOH) [18] in the
synthetic schemes. However, this modi¢cation (for in-
stance ZAhx5L3VS-PhOH compared to ZAhx5L3VS 4)
led to a considerable drop in inhibition (data not shown)
and was not pursued further. Iodination of the phenol
moiety in 11, as in AdaY(I)Ahx3L3VS 11-I, chemically
equivalent to its radioiodinated counterpart, results in
the same inhibition pro¢le as that observed for its non-
iodinated counterpart. Introduction of a (O)-biotin-lysine
residue, as in AdaK(Bio)Ahx3L3VS 17 results in a slight
drop of inhibition (Fig. 4B). However, 17 still compares
favorably to the smaller peptide vinyl sulfones. Simple
replacement of the Ada moiety with biotin, as in bio-
tinAhx3L3VS, resulted in a steep drop in inhibition (data
not shown), underscoring the importance of the Ada moi-
ety at this position distal from the pharmacophore.
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In the next set of experiments, we examined labeling
e⁄ciency of AdaY(125I)Ahx3L3VS 11-125I (Fig. 5). The
choice of 125I as label was made because of the ease of
detection of this isotope by autoradiography. EL-4 lysates
were treated with 0^30 WM ZL3VS, NLVS, YL3VS, epox-
omicin, AdaYAhx3L3VS 11 and AdaY(I)Ahx3L3VS 11-I,
respectively, prior to labeling with 11-125I (Fig. 5B). Im-
portantly, application of the new radiolabeled probe im-
proved resolution (compare to for instance 125I-NLVS) of
the proteasomal subunits, with four of the six possible
L-subunits clearly resolved. The di¡erent competitors
could now be compared in a straightforward manner. As
expected, NLVS and ZL3VS inhibit labeling mainly of
L5/L5i, whereas YL3VS preferentially blocks labeling of
L2/L2i. Of note, NLVS and YL3VS inhibit at much
higher concentrations than was observed in the reverse
experiment (inhibition of labeling with 125I-YL3VS or
125I-NLVS with 11 and 11-I, see Fig. 4B). Both
AdaYAhx3L3VS 11 and AdaY(I)Ahx3L3VS 11-I compete
for labeling of all subunits in a concentration range com-
parable to that for epoxomicin.
Two-dimensional (2D) SDS^PAGE analysis of EL-4 ly-
sate labeled with AdaY(125I)Ahx3L3VS 11-125I showed
that most proteasomal subunits were labeled roughly
equally well (Fig. 5A). With the possible exception of
L5, all subunits are clearly visible, including L1, which is
usually the most resistant towards active site labels. Note
that this experiment shows labeling of an otherwise un-
fractionated cell extract; the selectivity of labeling is evi-
dent.
A similar experiment was carried out with
AdaK(Bio)Ahx3L3VS 17, followed by detection of labeled
L-subunits by means of a streptavidin-horseradish peroxi-
dase conjugate. The L2, L2i and L5i subunits are labeled,
but labeling of L1 is less obvious (Fig. 5A). Although less
e⁄cient than the corresponding radiolabel (11-125I), bio-
tinylated proteasome inhibitor 17 readily allows detection
of both constitutive and immunoproteasomal subunits.
Both AdaY(125I)Ahx3L3VS 11-125I and AdaK(Bio)-
Ahx3L3VS 17 label all three subunits of the constitutive
proteasome in NIH-3T3 lysates (Fig. 5A). The mere intro-
duction of the biotin moiety a¡ects the pattern of labeling,
showing again the e¡ect of modi¢cations at considerable
distance from P1 on the L-subunits targeted.
The time-dependent labeling of EL-4 lysates with
AdaY(125I)Ahx3L3VS 11-125I was assayed next (Fig. 5C).
Comparison with 125I-NLVS and 125I-YL3VS revealed that
all targeted subunits are modi¢ed at a comparable rate,
with modi¢cation by AdaY(125I)Ahx3L3VS 11-125I being
possibly slightly faster (labeled bands are normalized
with the most densely labeled band at 100%).
2.5. N-terminally extended peptide vinyl sulfones block
hydrolysis of £uorogenic substrates
The inhibition of proteasome-mediated substrate hydro-
lysis with selected proteasome inhibitors was measured
(Table 1). We performed our kinetic measurements not
on crude EL-4 extracts, but rather on 20S proteasomes
puri¢ed from rabbit muscle as a more convenient source
from which large amounts of 20S proteasomes could be
prepared [8]. This preparation also eliminates any con-
founding e¡ects that might arise from the presence of
L1i, L2i and L5i. Puri¢ed 20S proteasome was incubated
with £uorogenic substrates (Suc-LLVY-AMC, to assay
chymotryptic activity ; Boc-LRR-AMC, to assay tryptic
activity, and Z-LLE-LNA, to assay PGPH activity) for
5 min to establish the initial rate of hydrolysis. Subsequent
inclusion of inhibitor allows the determination of the
kinetic constants for inhibition. ZAhx5L3VS 4,
AdaAhx3L3VS 7 and AdaYAhx3L3VS 11, as well as the
a⁄nity label AdaK(Bio)Ahx3L3VS 17, were compared
Table 1
Potency of N-terminally extended peptide vinylsulfones for inhibition of the 20S proteasome activitiesa
Compounds kobs/[I] (M31 s31)
Chymotryptic-like activity Trypsin-like activity PGPH activity
(1) AdaAhx3L3VS 7 8 200 þ 2 000 (0.05^0.01 WM)b 700 þ 180 (1^5 WM) 1 024 þ 350 (0.5^1 WM)
(2) AdaYAhx3L3VS 13 11 500 þ 2 000 (0.05^0.1 WM) 240 þ 40 (1^5 WM) 604 þ 160 (1^2 WM)
(3) AdaK(Bio)Ahx3L3VS 17 10 000 þ 1 500 (0.05^0.1 WM) 40 þ 13 (5^10 WM) 200 þ 30 (2^5 WM)
(7) ZAhx5L3VS 4 3 300 þ 800 (0.2^0.5 WM) 85 þ 19 (10^20 WM) 102 þ 52 (2^5 WM)
(6) NLVS 4 500 þ 1 100 (0.1^0.2 WM) 4 þ 1 (50^250 WM) 14 þ 3 (25^50 WM)
(9) YL3VS 70 þ 15 (5^10 WM) 174 þ 22 (5^10 WM) 8 þ 3 (10^50 WM)
(8) Epoxomicin 10 000 þ 2 000 (0.1^0.5 WM) 80 þ 22 (5^10 WM) 21 þ 7 (5^10 WM)
aSee Section 5.
bValues in parentheses indicated the range of inhibitor concentration used.
6
Fig. 5. Development of a novel set of radio- and a⁄nity probes. A: 1D and 2D gel analysis of EL-4 and HeLa cell lysates labeled with either
AdaY(125I)Ahx3L3VS 11-125I or AdaK(Bio)Ahx3L3VS 17. B: Labeling of proteasomal L-subunits with AdaY(125I)Ahx3L3VS 11-125I is e⁄ciently blocked
by AdaYAhx3L3VS 11, AdaY(I)Ahx3L3VS 11-I, epoxomicin, but not NLVS, YL3VS and ZL3VS. C: AdaY(125I)Ahx3L3VS 11-125I, 125I-YL3VS and
125I-NLVS display comparable rates in proteasomal L-subunit labeling. Labeled bands are normalized with the most densely labeled band at 100%.
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with the standard inhibitors NLVS, YL3VS and epoxomi-
cin (Table 1). All four compounds 4, 7, 11 and 17 block
the chymotryptic-like activity (hydrolysis of Suc-LLVY-
AMC) with an e⁄ciency comparable to that of NLVS
and epoxomicin. With the exception of
AdaK(Bio)Ahx3L3VS 17, the same holds true for inhibi-
tion of hydrolysis of Boc-LRR-AMC when compared to
YL3VS. Apparently, L1 and L5 are less sensitive to the
nature of the N-terminal extension than L2.
The inhibition of hydrolysis of £uorogenic peptides cor-
roborates the e⁄cient inhibition of labeling as described
before. Both AdaAhx3L3VS 7 and AdaYAhx3L3VS 11
strongly inhibited the PGPH activity, to an extent similar
or better than that of the PGPH-speci¢c inhibitor Ac-
GPFL-KP,LP-epoxyketone [22]. A comparison of absolute
values for the published kinetic studies is complicated by
the use of puri¢ed proteasomes from di¡erent sources and
the use of di¡erent £uorogenic peptide substrates. In our
assays we did not include strong detergents such as SDS,
often added to activate latent 20S proteasomal activity.
Nonetheless, the kinetic parameters we established for
the inhibitors used here are in good agreement with the
published values. The ability of N-terminally extended
peptide vinyl sulfones to inhibit all three catalytically ac-
tive L-subunits roughly equally well, combined with their
stronger inhibitory properties (compared to NLVS,
YL3VS and epoxomicin), so far makes them unique. In
comparison, peptide boronates display e⁄cient inhibition
of both chymotryptic and PGPH activities but consider-
ably less inhibition of the tryptic-like activity [20].
The type of assay used here, although useful for a qual-
itative assessment of inhibition activity, does not allow
comparison of absolute numbers obtained for the individ-
ual activities as a means to determine subunit speci¢city.
Fig. 6. AdaAhx3L3VS inhibits proteasomal proteolysis in living cells. A: Deglycosylated MHC I HC (HLA-A2) accumulates when proteasomal degrada-
tion is blocked in US11+ cells. ZL3VS and AdaAhx3L3VS 7, but not ZAhx5L3VS 4, AdaYAhx3L3VS 11 and AdaK(Bio)Ahx3L3VS 17 (50 WM ¢nal
concentration), inhibit degradation of HC and allow accumulation of the deglycosylated HC intermediate. B: Cells were incubated with a solvent con-
trol (lane 1), ZL3VS 1 (lane 2), ZAhx5L3VS 4 (lane 3) and AdaAhx3L3VS 7 (lane 4) (50 WM inhibitor concentration) for 6 h, ¢xed, followed by blue
nuclear staining of the DNA with DAPI (blue). Confocal laser scanning microscopy revealed that both ZL3VS 1 and AdaAhx3L3VS 7 inhibit degrada-
tion of HLA-A2 with equal e⁄ciency, as indicated by the levels of cytoplasmic green £uorescence. C: AdaAhx3L3VS 7 is a more potent inhibitor than
ZL3VS 1 on living cells. The proteasome inhibitors 1 and 7 were incubated at the indicated concentrations with U373 cells expressing US11 and GFP-
A2. Accumulation of green £uorescence due to the presence of GFP-A2 in the cytosol was measured by £ow cytometry.
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The numbers reported for inhibition of the chymotryptic-
like activity are almost always higher than those reported
for the tryptic-like and PGPH activities, possibly due to
di¡erent binding a⁄nity and reactivity of the individual
catalytic sites towards the £uorogenic substrates used. For
instance, whereas £uorogenic assay of AdaYAhx3L3VS 11
would suggest L5 as the preferred target, direct labeling of
HeLa lysate (see Fig. 5) revealed equal labeling of L2 and
L5, with slightly less labeling of L1. A further caveat is the
common use of puri¢ed 20S proteasome, which may not
re£ect cleavage behavior under physiological conditions.
We therefore believe that labeling experiments of cell ex-
tracts, which contain the 26S proteasome, in combination
with competition assays, to be the most accurate way to
assess subunit speci¢city of potential proteasome inhibi-
tors.
2.6. AdaAhx3L3VS 7 blocks proteasome-mediated cytosolic
proteolysis in living cells
Inhibition of proteasomal activity in vivo with
ZAhx5L3VS 4, AdaAhx3L3VS 7, AdaYAhx3L3VS 11 and
AdaK(Bio)Ahx3L3VS 17 was compared with the known
cell-permeable inhibitor ZL3VS (Fig. 6). To this end we
used an in vivo assay with cells that express the human
cytomegalovirus US11 gene (US11+ cells). The US11 gene
product accelerates degradation of MHC I heavy chain
(HC) molecules by promoting their dislocation from the
endoplasmic reticulum to the cytosol [33]. At this stage,
the single N-glycan is removed from the HC, followed by
proteasome-mediated degradation of the resulting poly-
peptide. In the presence of proteasome inhibitors, the de-
glycosylated class I HC accumulates transiently, as visual-
ized by a pulse-chase experiment [33]. In the absence of
proteasome inhibitor, degradation of class I HC is com-
plete within the 30 min chase period (Fig. 6A). Addition of
ZL3VS allows recovery of deglycosylated HC. A similar
result is obtained upon incubation of US11+ cells with
AdaAhx3L3VS 7, demonstrating its ability to cross the
cell membrane and inhibit proteasomal function in living
cells. Treatment with ZAhx5L3VS 4, AdaYAhx3L3VS 11
or AdaK(Bio)Ahx3L3VS 17 did not result in any accumu-
lation of deglycosylated class I HC (Fig. 6A), showing that
these inhibitors are unable to cross the cell membrane.
Inclusion of these inhibitors does not a¡ect metabolic la-
beling and cellular integrity, demonstrating the absence of
detergent-like properties.
In an independent experiment we examined the ability
of ZAhx5L3VS 4 and AdaAhx3L3VS 7 to inhibit the
breakdown of a di¡erent reporter, a green £uorescent pro-
tein (GFP)-tagged version of HLA-A2 (GFP-A2). When
expressed in US11+ cells, the GFP-A2 HC is destroyed,
and only background £uorescence is observed (D. Torto-
rella, E. Fiebiger and H.L. Ploegh, unpublished results).
Inclusion of external ZL3VS or AdaAhx3L3VS 7 resulted
in a time-dependent increase of cytoplasmic £uorescence,
consistent with the dislocation model proposed earlier
(Fig. 6B). While AdaAhx3L3VS 7 allowed accumulation
of GFP-A2, ZAhx5L3VS 4 did not. These experiments
con¢rm the cell permeability of AdaAhx3L3VS 7, but
not ZAhx5L3VS 4. When compared directly with ZL3VS,
we observed that in living cells AdaAhx3L3VS 7 is a far
more (10-fold) potent inhibitor, as assayed by accumula-
tion of the GFP-HLA-A2 reporter protein in the cytosol
(Fig. 6C).
3. Discussion
Resolving the substrate speci¢city of the three individual
catalytic activities in the constitutive proteasome, com-
bined with that of their IFNQ-inducible counterparts, is a
complicated task. An ideal tool to study proteasomal ac-
tivity would be a set of molecules that mimic the natural
substrate, and are equipped with a reporter entity. How-
ever, the nature of the proteasome dictates that any such
molecule that resembles too closely the natural polypep-
tide substrate will most likely be processed by one of the
catalytic L-subunits while reporting on the activity of a
neighboring L-subunit, as we have observed for oligopep-
tide vinyl sulfones (B.M. Kessler and H.L. Ploegh, unpub-
lished results). It is therefore not surprising that the con-
siderable literature on peptide-based tools to study the
proteasome, either £uorogenic substrates or inhibitors,
mostly describe modi¢ed peptides limited in length to
four amino acid residues. From these studies, selective
£uorogenic substrates as well as inhibitors for the individ-
ual catalytic L-subunits have emerged. These are valuable
tools to study the role of the individual L-subunits, both in
vitro and in living cells. Longer substrate analogs need to
be explored as inhibitors, on the premise that such com-
pounds might better mimic the unfolded polypeptide that
is the physiological substrate of the proteasome.
Here, we have presented a new class of substrate-like
proteasome inhibitors that e⁄ciently inhibit most protea-
somal subunits. Our data suggest a considerable overlap
between the individual catalytic activities of the protea-
some when assayed with these compounds. The new pro-
teasome inhibitors are based on a trileucine vinyl sulfone
core as the C-terminal portion, a sequence previously
shown to be capable of binding to the active site of the
catalytic L-subunits. Extension has been accomplished by
the introduction of a number of Ahx modules followed by
di¡erent N-caps. We chose extension with Ahx spacers, as
opposed to alkyl chains, to avoid complications that might
arise from detergent-like properties of compounds with
long alkyl chains. Reporter molecules, either radioiodi-
nated tyrosine or biotinylated lysine, are placed near the
N-terminus. The e⁄ciency of both AdaY(125I)Ahx3L3VS
11-125I and AdaK(Bio)Ahx3L3VS 17 to label proteasomal
subunits indicates the resistance of this class of com-
pounds to proteolytic cleavage. Labeled L-subunits can
CHBIOL 133 10-9-01 Cyaan Magenta Geel Zwart
Research Paper Extended proteasome inhibitors B.M. Kessler et al. 923
of course be visualized only if both the C-terminal vinyl
sulfone and the N-terminal label at a distance are retained.
The results presented here demonstrate the marked in-
£uence of extension, combined with the size of the N-ter-
minal cap, on both activity and selectivity of proteasome
inhibition. Regardless whether 125I-YL3VS or 125I-NLVS
is used as the active site label, the most potent inhibitors
of active site labeling, ZAhx5L3VS 4, AdaAhx3L3VS 7 and
AdaYAhx3L3VS 11, show a remarkably equal inhibition
pro¢le towards all proteasomal subunits assayed. This po-
tent inhibition pro¢le with little apparent discrimination
for the individual L-subunits has, to our knowledge, not
been demonstrated previously. Of interest are two litera-
ture examples describing comparable extended proteasome
inhibitors. For instance, epoxomicin derivatives equipped
with a biotin moiety through several Ahx residues were
proven to be e⁄cient a⁄nity reagents for several, but
not all, catalytic L-subunits [31,32]. Furthermore, two tri-
leucine aldehyde molecules linked through polyethylene
glycol spacers corresponding in size to lengths up to
25 amino acid residues have been shown to be potent
proteasome inhibitors and inactivate predominantly the
two trypsin-like and chymotrypsin-like activities in both
L-rings simultaneously [34,35].
Analysis of substrate hydrolysis essentially con¢rmed
the overall inhibition pro¢le of the most potent inhibitors,
although here ZAhx5L3VS 4 turns out to be 3^10-fold less
active than AdaAhx3L3VS 7 and AdaYAhx3L3VS 11.
However, it should be noted that in the di¡erent assays
di¡erent populations of proteasomes are used (either 26S
for EL-4 cell extracts or rabbit 20S proteasomes for £uo-
rogenic substrate assays).
The considerable overlap displayed by the individual
catalytic L-subunits in recognizing our inhibitors corrobo-
rates by studies that address the proteasome-mediated di-
gestion in vitro of entire proteins [6,7]. For instance, the
436 amino acid residue protein enolase I was digested with
puri¢ed yeast 20S proteasome, as well as several mutant
versions of 20S proteasomes in which individual catalytic
L-subunits were genetically incapacitated. Several remark-
able observations, indicating a high substrate redundancy
between the three catalytic subunits, were made. Thus,
although cleavage after acidic and basic residues was
clearly attributed to the L1/Pre3 subunit and the L2/Pup1
subunit, respectively, activity of these subunits was by no
means restricted to cleavage of sites uniquely displaying
these amino acids. Furthermore, the complexity, number
and average length (approximately eight residues) of the
degradation products (s 400 oligopeptides) did not vary
drastically using either wild-type or mutant proteasomes
(including a mutant in which both L1/Pre3 and L2/Pup1
were inactivated), indicating considerable overlap between
the individual catalytically active proteasomal L-subunits.
Similar observations were made in studies with mamma-
lian proteasomes, in which L5, but not L1 and L2, were
pharmacologically disabled by the covalent inhibitor
NLVS [36]. Such overlap is not surprising, given the fact
that proteasomes of the archaebacterium Thermoplasma
acidophilum, composed of 14 identical K-subunits and
14 identical L-subunits, are obviously capable of process-
ing polypeptides but must do with only a single type of
catalytic L-subunit.
It is tempting to assume that more e⁄cient proteasome
inactivation can be obtained by simply extending the size
of a given inhibitor. However, the steep loss of inhibition
observed by replacement of the N-terminal Ada to Ac as
in AcAhx3L3VS 13 and AcYAhx3L3VS 14 suggests a more
complicated mode of action. Apparently, elements distal
from the active site can strongly in£uence the inhibitory
properties. Given the nature of the acetyl group, which
can be regarded as a truncated Ahx residue (and therefore
AcAhx3L3VS 13 as a truncated ZAhx5L3VS 4), it seems
likely that steric reasons (a di¡erent folding of the com-
pound inside the proteolytic chamber), rather than chem-
ical properties, account for the change in inhibitory activ-
ity.
Labeling and competition experiments with
AdaY(125I)Ahx3L3VS 11-125I con¢rmed the high binding
activity and lack of discrimination between the individual
catalytic L-subunits. Competition of labeling of L2 and
L5/L5i with either YL3VS or NLVS could only be accom-
plished at relatively high concentrations of inhibitor,
whereas both AdaYAhx3L3VS 11 and AdaY(I)Ahx3L3VS
11-I proved to be as e⁄cient as epoxomicin in blocking
radiolabeling. 2D analysis of EL-4 lysates revealed a re-
markably equal distribution over ¢ve of the six catalytic
L-subunits present, with the exception of L5. HeLa cells,
expressing the constitutive proteasome, show equal label-
ing of L2 and L5, with a slightly lower intensity of L1.
Interestingly, the same loss of subunit speci¢city was ob-
served upon elongation of YL3VS (with a preference for
L2/L2i) with the AdaAhx3 moiety. Although slightly less
e⁄cient than the corresponding AdaY(125I)Ahx3L3VS,
AdaAhx3Y(125I)L3VS labeled all proteasomal subunits
with almost equal intensity (data not shown).
The identi¢cation of AdaAhx3L3VS 7 as a powerful,
general inhibitor of all proteasomal activities provides
new tools for the study of the proteasome. First of all,
AdaAhx3L3VS 7 blocks proteasome-mediated hydrolysis
in living cells at least 10 times better than ZL3VS. Fur-
thermore, both AdaK(Bio)Ahx3L3VS 17 and especially
AdaY(125I)Ahx3L3VS 11-125I are potent, general protea-
some labels.
In order to study the roles of the constitutive protea-
some and the immunoproteasome, it would be of great
interest to develop novel probes that can discriminate be-
tween the two species. In this respect, the emerging view is
that di¡erences between the constitutive proteasome and
the immunoproteasome concern not only preferred cleav-
age sites [37] but also the length of the oligopeptide prod-
ucts. Immunoproteasomes produce N-terminally extended
antigen precursors, favoring the generation of antigenic
CHBIOL 133 10-9-01 Cyaan Magenta Geel Zwart
924 Chemistry & Biology 8/9 (2001) 913^929
peptides for MHC I presentation [38]. The extended pep-
tide vinyl sulfones reported here, which can be modi¢ed at
will using the safety catch strategy, may help in the gen-
eration of inhibitors that better discriminate between the
constitutive proteasome and the immunoproteasome.
4. Signi¢cance
The 26S proteasome is involved in many important bio-
logical processes. It degrades most cytosolic proteins and
generates antigenic peptides presented by MHC I mole-
cules. The constitutive proteasome contains three individ-
ual catalytic activities, L1, L2 and L5, each of which occur
twice in the inner 20S core responsible for proteolysis.
Upon exposure to IFNQ, APCs assemble a new proteolytic
particle, the immunoproteasome, in which the three cata-
lytic L-subunits from the constitutive proteasome are re-
placed with three distinct, but highly homologous catalytic
activities L1i, L2i and L5i, respectively.
The physiological role and substrate speci¢city of the
individual catalytic L-subunits of the proteasome are
widely studied. Based on preferred cleavage of £uorogenic
peptide substrates, activities of the proteasome have been
classi¢ed as ‘chymotryptic-like’ (L5), ‘tryptic-like’ (L2) and
‘PGPH’ (L1). Studies with protein substrates, however,
indicate a far more complicated cleavage preference, with
considerable overlap between the individual catalytic ac-
tivities. We have generated a new set of peptide-based
proteasome inhibitors extended signi¢cantly at the N-ter-
minus when compared to the reported tri- and tetrapep-
tide-based inhibitors. Compared to these relatively small
inhibitors, inhibition in vitro of the proteasome is greatly
enhanced with our new compounds, while subunit specif-
icity is largely obliterated. These results re£ect the exten-
sive overlap in speci¢city of the individual catalytic sub-
units as observed with in vitro protein degradation.
5. Materials and methods
5.1. General
Amino acid building blocks and peptide synthesis reagents
were purchased from Advanced ChemTech, Peptides Internation-
al, Novabiochem and American Bioanalytical (piperidine, diiso-
propylethylamine, tri£uoroacetic acid). Adamantane-acetic acid,
TIS and iodoacetonitrile were purchased from Aldrich, iodoace-
tonitrile was passed over a basic alumina plug prior to use.
4-Sulfamylbutyrylaminomethyl polystyrene resin was purchased
from Novabiochem AG. Proteasome substrates (Suc-LLVY-
AMC, Boc-LRR-AMC, Z-LLE-LNA) were purchased from
Bachem. Epoxomicin was purchased from A⁄niti. Iodo-gen
was purchased from Pierce. Leucine vinyl sulfone, YL3VS,
NLVS and 4-hydroxy-3-nitrophenylacetyl-leucinyl-leucinyl-leu-
cine vinyl sulfone (NPL3VS) were prepared as reported [15,16].
HPLC-grade organic solvents DMF, dichloromethane, acetoni-
trile, NMP (American Bioanalytical) and ethyl acetate (Fisher)
were used as received. Sep-pak C18 columns were purchased from
Waters. SPPS was carried out using a 180‡ Variable Rate Shaker
(Peptides International). Nuclear magnetic resonance (NMR)
spectra were recorded on a Varian 500 MHz spectrometer,
mass spectra were recorded on an electrospray LCZ liquid chro-
matography^mass spectrometry (LC^MS) instrument (Micro-
mass). Preparative reverse phase HPLC puri¢cations were carried
out using a Waters PrepLC1 C18 column (250 mmU40 mm) with
a solvent gradient ranging from 30 to 95% acetonitrile in water
containing 0.1% formic acid.
5.2. Synthesis of the novel proteasome inhibitors
Route A (compounds 1^17) : Fmoc-Leu safety catch resin (50^
100 Wmol), prepared from Fmoc-Leu-OH and 4-aminosulfonyl-
butyryl polystyrene resin according to the literature procedure
[26], was elongated by standard Fmoc-based SPPS. In brief,
cleavage of the Fmoc protective group was accomplished by
treatment of the resin with 20% (v/v) piperidine in DMF. Peptide
coupling steps were performed using a ¢ve-fold excess of the
appropriate amino acid building block (respectively Fmoc-Leu-
OH, Fmoc-6-Ahx-OH, adamantane-acetic acid, Fmoc-Lys-(O-bio-
tin)-OH, Fmoc-Dpr-(NHL-Fmoc)-OH and Fmoc-Tyr-(OBu)-
OH) which was pre-activated with PyBOP (¢ve equivalents)
and DiPEA (six equivalents) in DMF. Coupling e⁄ciencies
were monitored with the Kaiser test, and couplings were repeated
when necessary. The obtained immobilized peptides were treated
with iodoacetonitrile (50 equivalents) and DiPEA (10 equivalents)
in NMP for 24 h under exclusion of light to a¡ord activated
safety catch resin, which was then reacted with leucine vinyl sul-
fone TFA salt (10 equivalents), in the presence of DiPEA
(12 equivalents) in DMF for 4 days. The reaction mixture was
diluted with ethyl acetate and extracted with 5% aqueous potas-
sium hydrogen sulfate (three times). The organic layer was dried
over MgSO4, ¢ltered and concentrated in vacuo. Removal of the
tert-butyl protective group (TFA/TIS/H2O 95/2.5/2.5 v/v, for
compounds 9^12, 15, 16) gave the crude peptides in 10^45% yield.
Preparative reverse phase HPLC a¡orded peptides 1^17 in 5^30%
yield in analytically pure form.
Method B (compounds 4, 7, 11, 17). Fmoc-Leu-Wang resin
(0.5^1.0 mmol) was elongated using standard Fmoc-SPPS. Treat-
ment of the immobilized peptides with TFA/TIS/H2O 95/2.5/2.5
v/v and removal in vacuo of the solvents were followed by
solution phase block coupling with leucine vinyl sulfone TFA
salt (one equivalent) under the agency of HBTU (one equivalent)
and DiPEA (2.2 equivalents) in DMF. After evaporation of
the solvent the residue was dissolved in ethyl acetate. Precipita-
tion of the product was accomplished by sonication for 2 min.
The precipitate was ¢ltered and washed with ethyl acetate, diethyl
ether and hexanes to a¡ord peptides 4, 7, 11, 17 in 40^55% yield
in 90^95% homogeneity, as judged by LC^MS and NMR analy-
sis.
5.3. Selected analytical data
ZL3VS 1 : MS: found 551.5 (M+H). 1H-NMR (DMSO-d6,
500 MHz): N 8.01^7.82 (m, 3H), 7.41^7.30 (m, 4H), 7.27^7.21 (m,
1H), 6.66 (dd, 1H, J 4.5 and 15.5 Hz), 6.60 (d, 1H, J 15.5 Hz),
4.99 (s, 2H), 2.98 (s, 3H), 1.62^1.22 (m, 9H), 0.94^0.80 (m, 18H).
ZAhxL3VS 2 : MS: found 665.3 (M+H). 1H-NMR (DMSO-
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d6, 500 MHz): N 8.02^7.80 (m, 4H), 7.41^7.30 (m, 4H), 7.27^7.21
(m, 1H), 6.66 (dd, 1H, J 4.5 and 15.5 Hz), 6.60 (d, 1H, J 15.5
Hz), 5.00 (s, 2H), 3.01^2.93 (m, 2H), 2.98 (s, 3H), 2.16^2.04 (m,
2H), 1.64^1.18 (m, 15H), 0.94^0.80 (m, 18H).
ZAhx3L3VS 3 : MS: found 892.1 (M+H). 1H-NMR (DMSO-
d6, 500 MHz): N 8.00^7.94 (m, 4H), 7.76^7.70 (m, 2H), 7.40^7.29
(m, 4H), 7.28^7.22 (m, 1H), 6.60 (dd, 1H, J 5.0 and 15.0 Hz),
6.60 (d, 1H, J 15.5 Hz), 4.99 (s, 2H), 4.59^4.52 (m, 1H), 4.29^4.22
(m, 2H), 3.03^2.94 (m, 6H), 2.98 (s, 3H), 2.18^2.09 (m, 2H), 2.05^
1.99 (m, 4H), 1.62^1.16 (m, 27H), 0.93^0.81 (m, 18H).
ZAhx5L3VS 4 : MS: found 1117.8 (M+H). 1H-NMR
(DMSO-d6, 500 MHz): N 7.99^7.92 (m, 4H), 7.76^7.70 (m,
4H), 7.39^7.28 (m, 4H), 7.26^7.21 (m, 1H), 6.55 (dd, 1H, J 5.0
and 15.0 Hz), 6.59 (d, 1H, J 15 Hz), 4.99 (s, 2H), 4.58^4.51 (m,
1H), 4.29^4.20 (m, 2H), 3.01^2.91 (m, 13H), 2.14^2.06 (m, 2H),
2.05^1.98 (m, 8H), 1.61^1.14 (m, 39H), 0.91^0.80 (m, 18H).
AdaL3VS 5 : MS: found 594.2 (M+H). 1H-NMR (DMSO-d6,
500 MHz): N 7.97 (d, 1H, J 8.5 Hz), 7.93 (d, 1H, J 8.5 Hz), 7.86
(d, 1H, J 7.5 Hz), 6.67 (dd, 1H, J 5.0 and 15.5 Hz), 6.59 (d, 1H,
J 15.5 Hz), 4.57^4.50 (m, 1H), 4.30^4.21 (m, 2H), 3.98 (s, 3H),
1.91^1.86 (m, 2H), 1.66^1.32 (m, 24H), 0.90^0.79 (m, 18H).
AdaAhxL3VS 6 : MS: found 707.6 (M+H). 1H-NMR
(DMSO-d6, 500 MHz): N 8.01^7.94 (m, 3H), 7.63 (t, 1H, J 5.5
Hz), 6.65 (dd, 1H, J 4.5 and 15.5 Hz), 6.59 (d, 1H, J 15.5 Hz),
4.58^4.50 (m, 1H), 4.28^4.19 (m, 2H), 3.00^2.94 (m, 2H), 2.98 (s,
3H), 2.14^2.05 (m, 2H), 1.89 (s, 2H), 1.66^1.19 (m, 30H), 0.91^
0.79 (m, 18H).
AdaAhx3L3VS 7 : MS: found 934.0 (M+H). 1H-NMR
(DMSO-d6, 500 MHz): N 7.80^7.96 (m, 3H), 7.75^7.70 (m,
2H), 7.65 (t, 1H, J 5.0 Hz), 6.65 (dd, 1H, J 5.0 and 15.0 Hz),
6.59 (d, 1H, J 15.5 Hz), 4.58^4.50 (m, 1H), 4.29^4.20 (m, 2H),
3.01^2.96 (m, 9H), 2.15^2.05 (m, 1H), 2.03^1.99 (m, 4H), 1.89 (s,
2H), 1.66^1.14 (m, 42H), 0.90^0.79 (m, 18H).
AdaAhx5L3VS 8 : MS: found 1160.4 (M+H). 1H-NMR
(DMSO-d6, 500 MHz): N 7.98^7.92 (m, 3H), 7.76^7.68 (m,
4H), 7.64 (t, 1H, J 5.0 Hz), 6.65 (dd, 1H, J 5.0 and 15.0 Hz),
6.59 (d, 1H, J 15.0 Hz), 4.59^4.50 (m, 1H), 4.30^4.21 (m, 2H),
3.01^2.95 (m, 13H), 2.15^2.05 (m, 1H), 2.03^1.99 (m, 8H), 1.89
(s, 2H), 1.66^1.15 (m, 54H), 0.90^0.80 (m, 18H).
ZYAhx3L3VS 9 : MS: found 1054.4 (M+H). 1H-NMR
(DMSO-d6, 500 MHz): N 7.99^7.88 (m, 5H), 7.74^7.69 (m,
2H), 7.40^7.21 (m, 6H), 6.69^6.62 (m, 3H), 6.59 (d, 1H, J 15.0
Hz), 4.95 (d, 1H, J 12.5 Hz), 4.91 (d, 1H, J 12.5 Hz), 4.57^4.50
(m, 1H), 4.28^4.20 (m, 2H), 4.11^4.04 (m, 1H), 3.06^2.94 (m,
9H), 2.79 (dd, 1H, J 5.0 and 13.5 Hz), 2.61 (dd, 1H, J 10.0
and 13.5 Hz), 2.15^2.04 (m, 2H), 2.04^1.98 (m, 4H), 1.61^1.12
(m, 27H), 0.91^0.79 (m, 18H).
ZYAhx5L3VS 10 : MS: found 1280.2 (M+H). 1H-NMR
(DMSO-d6, 500 MHz): N 7.98^7.88 (m, 5H), 7.77^7.68 (m,
4H), 7.38^7.20 (m, 6H), 6.68^6.63 (m, 3H), 6.59 (d, 1H, J 15.5
Hz), 4.96 (d, 1H, J 12.5 Hz), 4.91 (d, 1H, J 12.5 Hz), 4.58^4.41
(m, 1H), 4.29^4.20 (m, 2H), 4.10^4.04 (m, 1H), 3.06^2.96 (m,
13H), 2.80 (dd, 1H, J 5.0 and 13.5 Hz), 2.61 (dd, 1H, J 10.0
and 13.5 Hz), 2.14^2.05 (m, 2H), 2.04^1.98 (m, 8H), 1.61^1.16
(m, 39H), 0.90^0.80 (m, 18H).
AdaYAhx3L3VS 11 : MS: found 1097.1 (M+H). 1H-NMR
(DMSO-d6, 500 MHz): N 8.12 (d, 1H, J 9.0 Hz), 7.98^7.92 (m,
3H), 7.85^7.80 (m, 2H), 7.75^7.68 (m, 2H), 6.99^7.97 (m, 2H),
6.67^6.58 (m, 4H), 4.58^4.50 (m, 1H), 4.41^4.35 (m, 1H), 4.28^
4.20 (m, 2H), 3.05^2.95 (m, 9H), 2.81 (dd, 1H, J 5.0 and 13,5
Hz), 2.62 (dd, 1H, J 9.8 and 13.5 Hz), 2.14^2.04 (m, 2H), 2.02^
1.96 (m, 4H), 1.80 (s, 2H), 1.60^1.24 (m, 42H), 0.91^0.80 (m,
18H).
AdaYAhx5L3VS 12 : MS: found 1323.2 (M+H). 1H-NMR
(DMSO-d6, 500 MHz): N 7.98^7.92 (m, 4H), 7.80 (t, 1H, J 5.5
Hz), 7.76^7.70 (m, 5H), 7.00^6.98 (m, 2H), 6.70^5.56 (m, 4H),
4.59^4.51 (m, 1H), 4.41^4.34 (m, 1H), 4.48^4.18 (m, 2H), 3.02^
2.94 (m, 13H), 2.82 (dd, 1H, J 5.0 and 13,5 Hz), 2.63 (dd, 1H,
J 10.0 and 13.5 Hz), 2.07^2.02 (m, 2H), 2.02^1.97 (m, 8H), 1.80
(s, 2H), 1.60^1.16 (m, 54H), 0.90^0.79 (m, 18H).
AcAhx3L3VS 13 : MS: found 799.6 (M+H). 1H-NMR
(DMSO-d6, 500 MHz): N 8.00 (d, 1H, J 8.5 Hz), 7.99^7.91 (m,
3H), 7.88 (t, 1H, J 5.5 Hz), 6.67 (dd, 1H, J 5.0 and 15.5 Hz), 6.59
(d, 1H, J 15.5 Hz), 4.58^4.51 (m, 1H), 4.28^4.19 (m, 2H), 3.01^
2.91 (m, 9H), 2.14^2.05 (m, 2H), 2.03^1.97 (m, 4H), 1.75 (s, 3H),
1.61^1.12 (m, 27H), 0.89^0.79 (m, 18H).
AdaDpr(Ada)Ahx3L3VS 14 : MS: found 1196.0 (M+H).
1H-NMR (DMSO-d6, 500 MHz): N 7.98^7.92 (m, 3H), 7.76^
7.70 (m, 4H), 7.62 (t, 1H, J 5.5 Hz), 6.67 (dd, 1H, J 5.5 and
15.0 Hz), 6.59 (d, 1H, J 15.0 Hz), 4.58^4.51 (m, 1H), 4.29^4.20
(m, 3H), 3.25^3.19 (m, 1H), 3.03^2.92 (m, 10H), 2.13^2.05 (m,
2H), 2.03^1.97 (m, 4H), 1.88 (bs, 4H), 1.65^1.17 (m, 57H), 0.90^
0.80 (m, 18H).
AcYAhx3L3VS 15 : MS: found 962.4 (M+H). 1H-NMR
(DMSO-d6, 500 MHz): N 8.00 (d, 1H, J 8.5 Hz), 7.98^7.91 (m,
4H), 7.88 (t, 1H, J 5.5 Hz), 7.74^7.69 (m, 2H), 6.91^6.88 (m, 2H),
6.68^6.55 (m, 4H), 4.58^4.51 (m, 1H), 4.35^4.28 (m, 1H), 4.28^
4.19 (m, 2H), 3.02^2.91 (m, 9H), 2.77 (d, 1H, J 5.0 and 14.0 Hz),
2.59 (dd, 1H, J 9.5 and 13.5 Hz), 2.14^2.05 (m, 2H), 2.03^1.97
(m, 4H), 1.75 (s, 3H), 1.60^1.11 (m, 27H), 0.89^0.78 (m, 18H).
AdaDpr(Ada)YAhx3L3VS 16 : MS: found 1359.2 (M+H).
1H-NMR (DMSO-d6, 500 MHz): N 7.97^7.91 (m, 3H), 7.86 (t,
1H, J 5.5 Hz), 7.79^7.21 (m, 5H), 7.67^7.62 (m, 1H), 6.95^6.93
(m, 2H), 6.68^6.55 (m, 4H), 4.58^4.50 (m, 1H), 4.33^4.28 (m,
1H), 4.27^4.21 (m, 2H), 3.25^3.19 (m, 1H), 3.03^2.92 (m, 10H),
2.76 (d, 1H, J 5.0 and 14.0 Hz), 2.57 (dd, 1H, J 9.5 and 13.5 Hz),
2.12^2.04 (m, 2H), 2.02^1.98 (m, 4H), 1.88 (s, 4H), 1.65^1.10 (m,
57H), 0.89^0.78 (m, 18H).
AdaK(Bio)Ahx3L3VS 17 : MS: found 1287.9 (M+H).
1H-NMR (DMSO-d6, 500 MHz): N 8.11 (d, 1H, J 8.5 Hz),
7.99^7.93 (m, 2H), 7.84 (d, 1H, J 8.0 Hz), 7.74^7.68 (m, 2H),
7.07 (d, 1H, J 10.5 Hz), 6.68^6.56 (m, 3H), 4.57^4.50 (m, 1H),
4.31^4.10 (m, 4H), 4.00^3.94 (m, 1H), 3.08^2.94 (m, 16H), 2.14^
2.08 (m, 2H), 2.04^1.98 (m, 4H), 1.88 (s, 2H), 1.62^1.16 (m, 54H),
0.91^0.80 (m, 18H).
5.4. Preparation of AdaY(I)Ahx3L3VS 11-I
AdaYAhx3L3VS 11 (0.01 mmol) was reacted for 15 min with
sodium iodide (0.01 mmol) and chloramine T (0.01 mmol) in a
20/20/2 mixture of DMF/acetonitrile/phosphate bu¡er (pH 7.4).
The reaction was quenched with aqueous Na2S2O5 and extracted
with ethyl acetate. After concentration in vacuo of the organic
solvent, the mixture of starting material, mono- and bisiodinated
compounds was puri¢ed by reverse phase HPLC to a¡ord homo-
geneous AdaY(I)Ahx3L3VS 11-I in 15% yield. MS: found 1222.4
(M+H).
5.5. Preparation of 125I-NLVS, 125I-YL3VS and
AdaY(125I)Ahx3L3VS
Radioiodination of the proteasome inhibitors was carried out
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as follows. Iodo-gen (100 Wg) was dissolved in phosphate bu¡er
(50 mM, pH 7.4, 10 Wl). Proteasome inhibitor (20 Wg; NPL3VS,
YL3VS or AdaYAhx3L3VS) in acetonitrile (30 Wl) was added and
the mixture was agitated for 2 min. Na125I (10 Wl aqueous solu-
tion, 1 mCi) was added in the mixture agitated for 2 min. The
radioiodinated proteasome inhibitor was separated using a Sep-
pak C18 column. Free iodine was washed away with phosphate
bu¡er pH 7.4 and the radiolabels 125I-NLVS, 125I-YL3VS and
AdaY(125I)Ahx3L3VS were eluted using acetonitrile. Fractions
of 1 ml were collected and the fractions containing most radio-
activity (typically 0.3^0.7U106 cpm/Wl) were used for radiolabel-
ing experiments.
5.6. Cell cultures and preparation of cell lysates
The mouse EL-4 cell line was cultured in RPMI and HeLa cells
in Dulbecco’s modi¢ed Eagle medium, both supplemented with
10% fetal calf serum, 1% glutamine and 1% penicillin/streptomy-
cin. The US11+ U373 cell line [39] was transfected with a GFP-
HLA-A2 fusion construct preceded by the Kb signal sequence. A
detailed description of the generation of this cell line will be
reported elsewhere. Preparation of cell lysates was performed as
previously described [17,18]. In brief, cells were washed twice with
cold phosphate-bu¡ered saline, pelleted and lysed with one vol-
ume of glass beads (6 106 microns, acid-washed; Sigma Chem.
Co., St. Louis, MO, USA) and an equal volume of homogeniza-
tion bu¡er (50 mM Tris pH 7.4, 1 mM dithiothreitol (DTT),
5 mM MgCl2, 2 mM ATP and 250 mM sucrose). The cells
were subjected to three rounds of vortexing for 1 min and cooled
on ice for 30 s. Beads, membrane fractions, nuclei and cell debris
were removed by centrifugation at 13 000 rpm for 30 min. The
protein content was assayed by BCA protein quanti¢cation
(Pierce).
5.7. Labeling of proteasomes and competition experiments
Labeled inhibitors (0.5U106 cpm) were added to 25 Wg of cell
lysates and incubated for 2 h at 37‡C unless noted otherwise.
Samples were quenched by adding 3U SDS sample bu¡er (1U
¢nal concentration), heated to 95‡C for 3 min and analyzed by
one-dimensional (1D) SDS^PAGE (12.5%) followed by autora-
diography. For 2D, non-equilibrium pH gradient SDS^PAGE
(NEPHGE), the samples were prepared by adding urea (8 M ¢nal
concentration) and NEPHGE sample bu¡er with Pharmacia am-
pholite pH 3^10. 2D NEPHGE SDS^PAGE analysis was per-
formed as described [18]. In labeling competition experiments,
the compounds 1^17, 11-I, NLVS, YL3VS and epoxomicin at
0.3, 1, 3, 10 and 30 WM ¢nal concentrations were added from
acetonitrile stocks (3% maximal ¢nal concentration of acetoni-
trile) to 25 Wg cell lysates and incubated for 30 min at room
temperature prior to the addition of either 125I-NLVS or 125I-
YL3VS. After incubation for 2 h at 37‡C, the samples were an-
alyzed by 12.5% SDS^PAGE and autoradiography. Labeled
polypeptide bands were quanti¢ed using an AlphaImager 2000
(Alpha Innotech Corporation).
5.8. Puri¢cation of 20S proteasome
Rabbit muscle 20S proteasome was puri¢ed as described pre-
viously [8].
5.9. Proteasome labeling with AdaK(Bio)Ahx3L3VS 17
Cell lysates (25 Wg) were incubated with 3 Wg AdaK(Bio)-
Ahx3L3VS 17 for 2 h at 37‡C, followed by addition of 3U
SDS sample bu¡er (1U ¢nal concentration) for SDS^PAGE.
For 2D NEPHGE SDS^PAGE, 30 Wl of samples was mixed
with 220 Wl of rehydration solution (8 M urea, 2% CHAPS,
0.5% IPG bu¡er (Amersham Pharmacia Biotech) pH 3^10, bro-
mophenol blue, 18 mM DTT) and subjected to ¢rst dimension
isoelectric focussing using a IPGphor isoelectric focussing system
(Amersham Pharmacia Biotech) and second dimension 12.5%
SDS^PAGE.
5.10. In vivo inhibition of proteasome-mediated proteolysis
Pulse-chase analysis experiments were carried out following the
literature procedure [39]. US11+ U373 cells were incubated with
50 WM inhibitor for 1 h prior to biochemical analysis.
5.11. Immuno£uorescence assay
Immuno£uorescence experiments were performed as reported
[40] with minor modi¢cations. US11/GFP-A2 U373 cells were
allowed to attach to slides overnight before incubation with the
respective inhibitors (50 WM ¢nal concentration) from a DMSO
stock (DMSO was used as a solvent control). After ¢xation with
4% formaldehyde for 20 min at room temperature cellular DNA
was stained with DAPI (Molecular Probes) according to the man-
ufacturer’s guidelines. Analysis of green £uorescence was per-
formed with a Bio-RDA MRC1024 confocal microscope. For
the quantitative analysis of the inhibition of proteasomal proteol-
ysis in living cells, the inhibitors were incubated at di¡erent con-
centrations with US11/GFP-A2 U373 cells up to 8 h at 37‡C. The
accumulation of green £uorescence due to proteasome inhibition
was measured by £ow cytometry (FACSCalibur, Becton Dick-
inson).
5.12. Enzyme kinetics assay
Peptide substrates Suc-LLVY-AMC, Boc-LRR-AMC or
Z-LLE-LNA (100 WM ¢nal concentration) were incubated with
20S proteasomes at 37‡C in 50 mM Tris^HCl (pH 7.5), 1 mM
DTT. After 10 min appropriate amounts of inhibitor were added
from DMSO stock solutions (1% DMSO ¢nal concentration)
and £uorescence of released 7-amino-4-methylcoumarin (excita-
tion 380 nm, emission 460 nm) or 2-naphthylamine (excitation
342 nm, emission 425 nm) was measured continuously for 45 min.
kobs values were obtained by ¢tting the data to a non-linear
least-squares ¢t equation for time-dependent or slow binding
inhibition [41], £uorescence = vst+[(v03vs)/kobs]W[13exp(3kobst)],
where v0 is the initial velocity that decays over time to a ¢nal
velocity, vs, with a rate constant, kobs. The kobs/[I] values given
are an average of three to ¢ve independent experiments with at
least two di¡erent inhibitor concentrations.
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